Cocrystal Pharma

Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. It focuses on the preclinical and early clinical stage antiviral compounds for unmet medical needs including influenza, Hepatitis C virus, and norovirus infections. The company was founded in 2008 and is headquartered in Bothell, WA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

COCP stock is on the move this morning after announcing promising news about its Covid-19 antiviral treatments. Here's what to know.

COCP Stock: Cocrystal Pharma Gains 40% on Big Covid-19 News

The stock price of Cocrystal Pharma, Inc. (Nasdaq: COCP) increased 59.68% pre-market as it went from $1.24 to $1.98. This is why it happened.

COCP Stock: From $1.24 to $1.98 (59.68% Increase) Pre-Market Explanation

Cocrystal Pharma Inc (NASDAQ: COCP) has announced progress on its COVID-19 antiviral drug candidates that target coronaviruses, including SARS-CoV-2, and it also plans to launch a second COVID-19 program with additional antiviral compounds for development, apart from CDI-45205. The company said that it had designed new chemical scaffolds to improve in vitro potency and pharmacokinetic properties.

Cocrystal Pharma Stock Gains After Laying Out Plans To Launch Another COVID-19 Antiviral Candidate

Outlines 2021 product pipeline milestones for COVID-19, influenza A and norovirus antiviral programs

Cocrystal Pharma Reports 2020 Financial Results, Provides Business Update Including Antiviral Program Milestones

BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.  (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will hold one-on-one investor meetings at the Virtual 33rd Annual Roth Conference being held March 15-17, 2021. A webcast of Cocrystal's presentation has been pre-recorded and is available on the Company's website here .

Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference

BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that management will present a company overview and hold virtual investor meetings at the H.C. Wainwright Global Life Sciences Virtual Conference being held March 9-10, 2021.

Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]

Cocrystal Pharma (COCP) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Cocrystal Pharma (COCP) Jumps: Stock Rises 7.3%

BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, provides the following summary of today's upcoming presentation by Cocrystal President Sam Lee, Ph.D. at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine. A live webcast of Dr. Lee's presentation, titled “Application of Structure-Based Drug Design Platform Technology for Developing Broad Spectrum, COVID-19, Influenza, and HCV Antivirals,” will be available at 9:50 a.m. Pacific time (12:50 p.m. Eastern time) by registering here . Dr. Lee's presentation will be available on the Cocrystal website here beginning Friday, January 22, 2021.

Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies

Precision Biosciences

Cocrystal Pharma (NASDAQ: COCP) shares are trading higher after the company announced it has completed all research obligations under the Merck exclusive worldwide license and collaboration agreement, and that Merck is now solely responsible for further development of the influenza A/B antiviral compounds. Cocrystal Pharma Inc is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

Why Cocrystal Pharma, Precision BioScience Are Trading Higher Today

Program advances within the agreement's initial two-year timeframe

Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement

BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, the SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces that its President Sam Lee, Ph.D. will be making a presentation at the virtual 3rd Annual reimagine Health Research Symposium, University of Arizona College of Medicine, being held January 21, 2021.

Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium

BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics, announces that management will present at NobleCon17, Noble Capital Markets' 17th Annual Investor Conference on Tuesday, January 19, 2021 at 2:15 p.m. Eastern time (11:15 a.m. Pacific time).

Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021

CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2

Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses

The stock price of Cocrystal Pharma, Inc. (NASDAQ: COCP) increased by 111.17% over the past week as it went from $0.90 per share on November 20 to $1.89 per share as of today. This is why it happened.

COCP Stock Price Increases 111.17% Over The Past Week: Why It Happened

Cocrystal Pharma (COCP) is on the move Wednesday even with there being a lack of news concerning the pharmaceutical company. The post Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock appeared first on InvestorPlace.

Cocrystal Pharma: 8 Things for COCP Investors to Know About the Biotech Stock

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

BOTHELL, WA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced that Dr. Gary Wilcox and Dr. Sam Lee, have been selected to present at the World Antiviral Conference on Thursday, November 12, 2020 at 1:20 PM EST. The Company's presentation titled, “Antivirals against coronavirus and the A strains of the influenza virus,” will be accessible to those registered to attend the virtual event.

Cocrystal Pharma Selected to Present at the World Antiviral Conference

– Live video webcast with the Cocrystal management team, on Thursday, November 12th at 12:00 PM EST –

Cocrystal Pharma to Present at the H.C. Wainwright 6th Annual Israel Conference

– New in vitro data demonstrating antiviral activity with lead compound CC-42344 against Xofluza (baloxavir)-resistant H1N1 strain –

Cocrystal Pharma Provides Update on Influenza A Program

BOTHELL, WA, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP) The following is being released by Cocrystal Pharma, Inc. pursuant to an order of the United States District Court, District of New Jersey, regarding Agreement of Settlement.

Cocrystal Pharma Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

– Live video webcast with Chairman and CEO, Dr. Gary Wilcox, on Monday, September 14th at 3:30 PM EDT –

Cocrystal Pharma to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

BOTHELL, WA, Aug.  31, 2020  (GLOBE NEWSWIRE) --   Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today the closing of its previously announced underwritten public offering of 16,422,813 shares of common stock of the Company, including the partial exercise by the underwriter of the option to purchase an additional 2,137,098 shares of common stock, at a price to the public of $1.05 per share.

Cocrystal Pharma Announces Closing of $17.2 Million Bought Deal Including Partial Exercise of Underwriter's Option to Purchase Additional Shares

BOTHELL, WA, Aug.  26, 2020  (GLOBE NEWSWIRE) --   Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that, due to demand, the underwriter has agreed to increase the size of its previously announced public offering and purchase on a firm commitment basis 14,285,715 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.

Cocrystal Pharma Increases Previously Announced Bought Deal to $15.0 Million

BOTHELL, WA, Aug.  26, 2020  (GLOBE NEWSWIRE) --   Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 9,523,810 shares of common stock of the Company, at a price to the public of $1.05 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about August 31, 2020, subject to satisfaction of customary closing conditions.

Cocrystal Pharma Announces $10.0 Million Bought Deal Offering

– COVID-19 program in preclinical development; Discussions with potential strategic partners ongoing –

News for Cocrystal Pharma Stock (COCP)